Share on StockTwits

Roth Capital began coverage on shares of Iradimed Corp (NASDAQ:IRMD) in a research note issued on Monday, reports. The firm set a “buy” rating and a $14.00 price target on the stock. Roth Capital’s price target points to a potential upside of 26.93% from the stock’s previous close.

Iradimed Corp (NASDAQ:IRMD) traded up 8.24% on Monday, hitting $11.939. The stock had a trading volume of 8,224 shares. Iradimed Corp has a 52 week low of $7.94 and a 52 week high of $11.27. The stock has a 50-day moving average of $9.21 and a 200-day moving average of $9.21. The company has a market cap of $124.4 million and a price-to-earnings ratio of 54.88.

iRadimed Corporation is a provider of non-magnetic intravenous (NASDAQ:IRMD) infusion pump systems that are safe for use during magnetic resonance imaging (MRI) procedures.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.